Impact of elevated systolic arterial pulmonary pressure on the total mortality rate after acute myocardial infarction in the elderly

Salim Bary Barywani¹,²*, Magnus C. Johansson¹,³, Silvana Kontogeorgos¹,³, Zacharias Mandalenakis¹,² & Per-Olof Hansson¹,²

Reduced left ventricular ejection fraction (LVEF) is associated with increased mortality after acute myocardial infarction (AMI). However, the prognostic impact of elevated systolic pulmonary artery pressure (sPAP) in the very elderly patients after AMI is lacking. We aimed to study the impact of elevated sPAP on one- and five-year all-cause mortality after AMI in very elderly patients, 80 years of age and older. Of a total number of 353 patients (≥ 80 years) who were hospitalized with acute coronary syndrome, 162 patients presenting with AMI and with available data of sPAP on echocardiography were included and followed-up for 5 years. The survival analyses were performed using Cox-Regression models adjusted for conventional risk factors including LVEF. Altogether 66 of 162 patients (41%) had ST-segment elevation MI, and 121 (75%) of patients were treated with percutaneous coronary intervention in the acute phase. Echocardiography during the admission revealed that 78 patients (48%) had a LVEF ≤ 45% and 66 patients (41%) had a sPAP ≥ 40 mmHg. After one and five years of follow-up, 23% (n = 33) and 53% (n = 86) of patients died, respectively. A multivariable Cox-Regression analysis showed that the elevated sPAP (≥ 40 mmHg) was an independent predictor of increased mortality in both one and five years after AMI; HR of 2.63 (95% CI 1.19–5.84, \( p = 0.017 \)) and HR of 2.08 (95%, CI 1.25–3.44, \( p = 0.005 \)) respectively, whereas LVEF ≤ 45% did not show any statistically significant impact, neither on one- nor on five-year mortality (HR 1.3, 95% CI 0.6–2.9, \( p = 0.469 \)) and (HR 1.4, 95% CI 0.8–2.4, \( p = 0.158 \)), respectively. Elevated sPAP was an independent risk factor for one- and five-year all-cause mortality after AMI in very elderly patients and sPAP seems to be a better prognostic predictor for all-cause mortality than LVEF. The risk of all-cause mortality after AMI increased with increasing sPAP.

Abbreviations
LVEF  Left ventricular ejection fraction
RA   Right atrium
sPAP Systolic pulmonary artery pressure
AMI   Acute myocardial infarction
STEMI ST-elevation myocardial infarction
Non-STEMI Non-ST-elevation myocardial infarction
PCI Percutaneous coronary intervention
IVC Inferior vena cava
eGFR Estimated glomerular filtration rate
BMI Body mass index
BP Blood pressure
ACEI Angiotensin converting enzyme inhibitors
ARB Angiotensin receptor blockers

¹Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. ²Department of Medicine, Geriatrics and Emergency Medicine, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden. ³Department of Clinical Physiology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden. *email: salim.barywani@gu.se
Heart failure (HF) after acute myocardial infarction (AMI) is associated with increased mortality and morbidity in all age groups. Previous studies have identified several risk factors for impaired survival after AMI, including reduced left ventricular ejection fraction (LVEF) as a marker for structural left ventricular systolic dysfunction. Several studies have demonstrated also the impact of elevated sPAP after AMI as an independent risk factor of increased all-cause mortality. These studies have included relatively young patients with relatively short-term follow-up. For instance, Delgado and co-authors in their well-designed study included patients with an average age of 65 years with a follow-up period of 1 year, Møller and co-authors in their study included patients with an average age of about 74 years with a follow-up period of 40 months and Fan and co-authors in their study included patients with an average age about 74 years and a follow-up period of about 6 months. Mutlak and co-authors performed a prospective longitudinal observational study designed to determine predictors of post myocardial infarction HF, and they demonstrated that 44% of the patients had a systolic pulmonary artery pressure (sPAP) > 35 mmHg. In addition, elevated sPAP at the index admission was a useful marker in unmasking latent subclinical HF and predicting the development of overt HF. Thus, the available evidence on the impact of sPAP on survival after AMI is mainly conducted in relatively young patients (<80 years) with a short-term follow-up. To the best of our knowledge, the prognostic impact of elevated sPAP on mortality in very elderly patients is not studied. In the present study we sought to investigate the impact of elevated sPAP on short-and long-term all-cause death after AMI in elderly patients ≥ 80 years.

Methods
Study cohort
Three hundred and fifty-three patients aged ≥ 80 years hospitalized due to acute coronary syndrome at the two major Cardiology departments at Sahlgrenska University Hospital (SU), affiliated with the University of Gothenburg during 2006–2007 were included consecutively. All patients presented with acute myocardial infarction and examined with echocardiography with adequate data on sPAP were included in the study and retrospectively followed up regarding all-cause death for 5 years (n = 162). Treatment with percutaneous coronary intervention (PCI) or not was based on a pure clinical decision made by the attending cardiologist. All PCIs were performed at a joint PCI center for both hospitals. Patients were retrospectively identified from the hospital patient registry. Patients from other hospitals who were referred to SU for PCI were excluded due to incomplete follow-up data. The study protocol was approved by the Ethical Committee at the University of Gothenburg.

Echocardiography
All echocardiography examinations were performed at the department of Clinical Physiology at Sahlgrenska University Hospital by trained echo technicians or physicians according to standardized protocol. Echocardiography examinations were performed after coronary angiography examinations in patients presented with STEMI and before coronary angiography examinations in patients presented with non-STEMI. However, all echocardiography studies were performed before discharge from the hospital. Echocardiography data including data on sPAP were retrieved from the echocardiography reports already performed for clinical purposes. LVEF was measured using Simpson biplane or when not feasible by visual estimate. Left atrial area was measured in apical 4 chamber view. LV filling pressure was qualitatively estimated by pulsed wave Doppler of mitral and pulmonary vein flow as increased or normal. Mitral regurgitation was analyzed by colour and continuous wave Doppler and considered present when there more than trace regurgitation. Aortic stenosis was considered present when the peak gradient was ≥ 25 mmHg. Reference values were those used in clinical praxis and were based on results from a previously examined local healthy population sample from which regression equations had been constructed based on sex, body surface area, weight and age. The equations were incorporated in a spreadsheet, resulting in a z-score and an increased parameter-value for an individual was defined as a z-score ≥ 2.0. The reference limits where thus individually calculated for each patient.

Estimation of systolic pulmonary artery pressure
Systolic pulmonary artery pressure (sPAP) was estimated by echocardiography from the tricuspid valve regurgitant jet velocity using the modified Bernoulli equation 4v² plus right atrial pressure. Special care was taken to align the Doppler cursor with the tricuspid regurgitation jet. Right atrial (RA) pressure was estimated from characteristics of the inferior vena cava (IVC); based on the diameter and the respiratory variation in the diameter of the IVC: an IVC diameter ≤ 21 mm that collapses > 50% with a sniff suggested a normal RA pressure of 5 mmHg, whereas an IVC diameter ≤ 21 mm that collapses < 50% or an IVC diameter > 21 mm that collapses > 50% with a sniff regarded as an intermediate value, 10 mmHg. AIVC diameter > 21 mm that collapses < 50% with a sniff or < 20% on quiet inspiration regarded as a high RA pressure of 15 mmHg.

Statistics
Categorical variable were described as percentages and compared using chi-square test or Fisher exact as appropriated. Continuous variables were described as means ± standard deviation (SD) and compared using independent sample test or One-way analysis of covariance. To adjust for the underlying baseline characteristics and to analyze for probable association between different levels of the sPAP and mortality, the cohort was analyzed using multivariable Cox proportional-hazard regression models analyzing time to event. The results were adjusted for all the baseline variables demonstrated in Tables 1 and 2 systematically, according to the principles.
Table 1. Demographic and clinical characteristics of the study patients, comparing patients with systolic arterial pulmonary pressure (sPAP) ≥ 40 mmHg and sPAP < 40 mmHg. BMI Body mass index, STEMI ST-elevation myocardial infarction, Non-STEMI Non-ST-elevation myocardial infarction, PCI Percutaneous coronary intervention, BP Blood pressure, eGFR Estimated glomerular filtration rate, ACEI Angiotensin converting enzyme inhibitors, ARB Angiotensin receptor blockers.

| Demographics                  | sPAP ≥ 40 mmHg (n = 66) | sPAP < 40 mmHg (n = 96) | P-value |
|-------------------------------|--------------------------|-------------------------|---------|
| Age, year                     | 84.4 ± 2.8               | 83.7 ± 2.8              | 0.089   |
| Gender, male                  | 32 (48.5)                | 58 (60.4)               | 0.133   |
| Weight, kg                    | 70.7 ± 15.4              | 73.2 ± 12.0             | 0.265   |
| Height, cm                    | 167.6 ± 22.2             | 169.5 ± 8.8             | 0.452   |
| BMI, kg/m²                    | 23.6 ± 3.7               | 25.4 ± 3.8              | 0.004   |
| Smoking, yes                  | 6 (9.5)                  | 5 (5.3)                 | 0.321   |
| Clinical characteristics      |                          |                         |         |
| STEMI, yes                    | 35 (53)                  | 38 (39.6)               | 0.74    |
| Non-STEMI, yes                | 31 (47.0)                | 58 (60.0)               | 0.091   |
| PCI, yes                      | 44 (66.7)                | 77 (80.2)               | 0.051   |
| Heart rate, bpm               | 81.8 ± 16.7              | 80.8 ± 29.7             | 0.881   |
| Systolic BP, mmHg             | 145.6 ± 28.6             | 150.4 ± 26.6            | 0.296   |
| Diastolic BP, mmHg            | 85.8 ± 16.1              | 82.8 ± 16.1             | 0.271   |
| Laboratory findings          |                          |                         |         |
| Hemoglobin, g/L               | 129.8 ± 15.2             | 131.7 ± 17.0            | 0.478   |
| eGFR, ml/min/1.73m²           | 49.1 ± 19.7              | 50.3 ± 18.3             | 0.682   |
| Creatinine, umol/L            | 110.0 ± 104.2            | 110.7 ± 77.6            | 0.961   |
| Comorbidities                 |                          |                         |         |
| Atrial fibrillation, yes      | 17 (27.0)                | 17 (17.7)               | 0.153   |
| History of heart failure, yes | 14 (23.0)                | 17 (17.7)               | 0.355   |
| Hyper tension, yes            | 35 (53.0)                | 40 (41.7)               | 0.103   |
| Diabetes, yes                 | 13 (21.0)                | 16 (17.6)               | 0.374   |
| Hyperlipidaemia, yes          | 9 (13.8)                 | 8 (8.3)                 | 0.195   |
| Previous stroke, yes          | 11 (19.6)                | 10 (11.0)               | 0.284   |
| Medications                   |                          |                         |         |
| β-Blockers, yes               | 34 (51.5)                | 51 (56.7)               | 0.317   |
| ACEI/ARB, yes                 | 20 (30.3)                | 26 (27.1)               | 0.517   |
| diuretics, yes                | 16 (24.2)                | 19 (20.9)               | 0.378   |
| Calcium channel blocker, yes  | 14 (21.2)                | 36 (39.1)               | 0.017   |
| Statins, yes                  | 11 (16.7)                | 21 (22.6)               | 0.238   |
| Digoxin, yes                  | 9 (15.0)                 | 10 (10.8)               | 0.296   |

Table 2. Echocardiographic characteristics of study patients, comparing patients with systolic arterial pulmonary pressure (sPAP) ≥ 40 mmHg and sPAP < 40 mmHg. sPAP Systolic pulmonary artery pressure.

| Echocardiographic characteristics | sPAP ≥ 40 mmHg (n = 66) | sPAP < 40 mmHg (n = 96) | P-value |
|----------------------------------|--------------------------|-------------------------|---------|
| Left ventricular ejection fraction, % | 41.7 ± 10.6             | 49.5 ± 10.4             | < 0.001 |
| Elevated left ventricular filling pressure, yes | 29 (43.9)              | 16 (21.6)               | < 0.001 |
| Dilated left ventricle, yes      | 16 (25.4)                | 15 (16.5)               | 0.125   |
| Dilated left atrium, yes         | 32 (54.2)                | 29 (30.2)               | 0.008   |
| Mitral valve regurgitation ≥ grad 1/4, yes | 37 (56.9)              | 23 (25.0)               | < 0.001 |
| Tricuspid valve regurgitation ≥ grad 1/4, yes | 9 (13.8)               | 4 (4.4)                 | 0.036   |
| Aortic valve stenosis, yes       | 16 (27.6)                | 11 (13.3)               | 0.029   |
of Cox-regression model building. That means the variables were first included in univariable models and only variables with a \( p \)-value < 0.05 have been included in the multivariable models which included 8 variables indicating about 11 events (86 events) per variable. To identify the lowest cut off level of the \( sPAP \) associated with increased mortality rate, multivariable models were built for different \( sPAP \) levels, as low as 30 mmHg and upward with 5 mmHg intervals. The multivariable Cox models were assessed for proportional hazard assumption for covariates graphically with adjusted log minus log curves. The hazard ratios (HRs) with confidence intervals (CIs) and \( p \)-values were presented. All statistical analyses were performed using SPSS 22 statistical software. \( p \)-value < 0.05 was regarded as statistically significant.

**Laboratory analysis**

All laboratory variables were analyzed, according to routine protocol, by the Clinical Chemistry Laboratory at Sahlgrenska University Hospital. Cockcroft–Gault formula was used to estimate the glomerular filtration rate (eGFR) in ml/min/1.73m\(^2\).

**Clinical outcome data**

The primary endpoints were one- and five-year all-cause mortality after acute myocardial infarction. Data on time of death were obtained from the Swedish Cause of Death registry which includes all deaths of persons registered in Sweden.

**Ethics approval and consent to participate**

The Ethical Committee at the University of Gothenburg approved and granted permission to access and use the medical records described in the study. The ethical committee also ruled that no formal consent was necessary. The protocol was performed in accordance with the relevant guidelines and regulations according to the declaration of Helsinki.

**Results**

**Clinical characteristics**

Of the whole cohort, about 41% of the patients had STEMI and 59% had non-STEMI with an average left ventricular ejection fraction (LVEF) about 46%. The target vessel was left descending coronary artery (LAD) in about 49% of the patients, circumflex coronary artery (Cx) in 14% and right coronary artery (RCA) in 11%. About 40% of the patients had anterior myocardial infarction (MI), 14% had inferior MI and 46% had MI with unspecified localization. The clinical characteristics of the patients, comparing patients with \( sPAP \geq 40 \text{ mmHg} \) with the patients with \( sPAP < 40 \text{ mmHg} \) are presented in Table 1. The \( sPAP \geq 40 \text{ mmHg} \) was the lowest \( sPAP \) level associated with increased mortality. Patients with \( sPAP \geq 40 \text{ mmHg} \) had lower BMI (23.6 ± 3.7 vs. 25.4 ± 3.8 kg/m\(^2\)) and were less frequently treated with calcium channel blocker (21.2% vs. 39.1%) compared to patients with a \( sPAP < 40 \text{ mmHg} \). There were no significant differences between the two groups in gender, previous stroke or in number of patients treated with PCI, betablockers, angiotensin converting enzyme inhibitors/angiotensin receptor blockers, diuretics, statins, or digoxin.

**Echocardiography findings**

Compared to patients with \( sPAP < 40 \text{ mmHg} \), patients with \( sPAP \geq 40 \text{ mmHg} \) more often had reduced LVEF (41.7% vs. 49.5%), elevated left ventricular filling pressure (43.9% vs. 21.6%), dilated left atrium (54.2% vs. 33.0%), mitral valve regurgitation (56.9% vs. 25.0%), tricuspid valve regurgitation (13.8% vs. 4.4%) and aortic valve stenosis (27.6% vs. 13.3%), Table 2.

**Outcome data**

After 5-years of follow-up 86 patients died (all-cause mortality: 53.0%) while the 1-year all-cause mortality was 23.4% (38 deaths). Patients with \( sPAP \geq 40 \text{ mmHg} \) had a higher mortality rate, 5-year mortality rate of 69.6% (46 events) and 1-year mortality rate of 34.8% (23 events), compared to patients with \( sPAP < 40 \text{ mmHg} \), 41.6% (40 events) \( (p < 0.001) \) for 5-year mortality rate and 15.6% (15 events) \( (p = 0.004) \) for 1-year mortality rate.

**Association between \( sPAP \) and 1-year mortality**

The association between \( sPAP \) and 1-year all-cause mortality is illustrated in Table 3. Multivariable analysis found a statically significant association between elevated \( sPAP \) and increased 1-year all-cause mortality rate with a cutoff level at \( \geq 40 \text{ mmHg} \) (HR 2.63, 95%CI 1.19–5.84, \( p = 0.017 \)), Fig. 1. As a continuous variable, every increase of 5 mmHg in \( sPAP \) was associated with 17% increased relative risk for all-cause mortality (HR = 1.034, 95% of CI 1.004–1.065 and \( p = 0.025 \)).

**Association between \( sPAP \) and 5-year mortality**

The association between \( sPAP \) and 5-year mortality is illustrated in Table 4. Cox proportional-hazard regression multivariable models adjusted for the baseline characteristics demonstrated a statistically significant association between elevated \( sPAP \) and increased all-cause mortality rate with a cutoff level at \( \geq 40 \text{ mmHg} \) (HR = 2.08, 95%CI 1.25–3.44, \( p = 0.005 \)), Fig. 2. As a continuous variable, every increase of 5 mmHg in \( sPAP \) was associated with 15% increased relative risk for all-cause mortality \( (HR = 1.030, 95\% \text{ of CI} = 1.008–1.052 \text{ and } p = 0.007) \).

Also, male gender (HR 1.9, 95%CI 1.1–3.2, \( p = 0.019 \)), atrial fibrillation (HR 2.04, 95%CI 1.22–3.40, \( p = 0.006 \)) and eGFR \( \leq 35 \text{ ml/min/1.73m}^2 \) (HR 2.35, 95%CI 1.37–4.01, \( p = 0.006 \)) were associated with increased 5-year
Table 3. Univariate and multivariable Cox-regression analysis of factors for association with 1-year all-cause mortality. All variable in Tables 1 and 2 were included in the univariable models.

| Variables                             | Univariable          |            | Multivariable       |            |
|---------------------------------------|----------------------|------------|---------------------|------------|
|                                       | HR (95% CI)          | p          | HR (95% CI)         | p          |
| Age, year                             | 1.03 (0.92–1.15)     | 0.602      | 0.97 (0.85–1.11)    | 0.639      |
| Gender, male                          | 0.79 (0.42–1.49)     | 0.471      | 0.97 (0.31–0.90)    | 0.518      |
| sPAP ≥ 40 mmHg                        | 2.46 (1.26–4.62)     | 0.008      | 2.63 (1.19–5.84)    | 0.017      |
| LVEF ≤ 45%                            | 1.71 (0.88–3.29)     | 0.111      | 1.34 (0.61–2.93)    | 0.469      |
| Diabetes Mellitus                     | 1.26 (0.57–2.75)     | 0.570      | 1.17 (0.49–2.77)    | 0.727      |
| Treatment with percutaneous coronary intervention (PCI) | 0.56 (0.29–1.09) | 0.086      | 0.72 (0.33–1.6)     | 0.424      |
| Atrial fibrillation                   | 0.89 (0.39–2.05)     | 0.791      | 0.78 (0.31–1.96)    | 0.601      |
| Estimated glomerular filtration rate ≤ 35 ml/min | 1.94 (0.96–3.95) | 0.067      | 1.99 (0.88–4.48)    | 0.097      |

Figure 1. Adjusted 1-year risk of mortality, comparison between patients with sPAP ≥ 40 and patients with sPAP < 40 mmHg.

Table 4. Univariate and multivariable cox-regression analysis of factors for association with 5-year all-cause mortality. All variable in Tables 1 and 2 were included in the univariable models. HR Hazard ratio, sPAP Systolic pulmonary artery pressure, LVEF Left ventricular ejection fraction.

| Variables                             | Univariable          |            | Multivariable       |            |
|---------------------------------------|----------------------|------------|---------------------|------------|
|                                       | HR (95% CI)          | p          | HR (95% CI)         | p          |
| Age, year                             | 1.09 (1.01–1.17)     | 0.021      | 1.02 (0.93–1.11)    | 0.693      |
| Gender, male                          | 0.97 (0.64–1.49)     | 0.891      | 1.1 (1.1–3.2)       | 0.019      |
| sPAP ≥ 40 mmHg                        | 2.21 (1.44–3.38)     | <0.001     | 2.08 (1.25–3.44)    | 0.005      |
| LVEF ≤ 45%                            | 1.26 (0.82–1.92)     | 0.293      | 1.42 (0.85–2.438)   | 0.158      |
| Diabetes Mellitus                     | 1.92 (1.17–3.14)     | 0.010      | 1.73 (1.01–2.96)    | 0.048      |
| Treatment with percutaneous coronary intervention (PCI) | 0.445 (0.29–0.69)  | <0.001     | 0.48 (0.29–0.82)    | 0.004      |
| Atrial fibrillation                   | 2.32 (1.47–4.36)     | <0.001     | 2.04 (1.22–3.40)    | 0.006      |
| Estimated glomerular filtration rate ≤ 35 ml/min | 2.19 (1.36–3.54) | 0.001      | 2.35 (1.37–4.01)    | 0.006      |
mortality rate. While treatment with percutaneous coronary intervention were associated with decreased 5-year mortality, (HR 0.48, 95%CI 0.29–0.82, \( p = 0.004 \)).

**Discussions**

The results of the present study demonstrate an association between elevated sPAP levels and one as well as five-year mortality rate after AMI in a cohort of elderly patients, all 80 years of age or older at the baseline. After multivariable adjustment, sPAP with a cutoff level at ≥ 40 mmHg was a strong independent predictor with a twofold increased risk for both one- and five-year all-cause mortality rate. Every increase of 5 mmHg in sPAP was associated with 17 and 15% increased relative risk for one- and five-year all-cause mortality, respectively.

To our knowledge, the present study is the first to analyze the impact of sPAP on one- and five-year prognosis after AMI in an elderly patient sample, ≥ 80 years. However, the impact of sPAP on survival after AMI have been demonstrated in several studied the last years\(^{14–17}\), but these studies compared with the present study were conducted in much younger patients with shorter follow-up periods. The results of the present study add more data to the available evidence supporting the impact of sPAP on both short- and long-term survival and in all patient age groups, including patients ≥80 years.

Interestingly, sPAP was a stronger predictor for both short- and long-term mortality, compared with LVEF which did not show any statistically significant impact in the Cox-regression multivariable models. These results indicate that sPAP as a marker of hemodynamic dysfunction\(^{21}\) after AMI is a stronger prognostic predictor, compared with the LVEF as a marker of structural LV dysfunction.

The multivariable Cox proportional-hazards regression models found sPAP ≥ 40 mmHg to be the only independent predictor for the one-year all-cause mortality after AMI. Whereas, independent predictors of increased five-year all-cause mortality, beside the sPAP ≥ 40 mmHg, were also diabetes mellitus and atrial fibrillation and eGFR ≤ 35 ml/min, while treatment with PCI had a survival protective effect. These results indicate that patients with elevated sPAP have a high risk for impaired survival already during the first year and these patients must be identified and tailored for secondary preventive managements as soon as possible.

**Pathophysiological mechanisms of elevated pulmonary artery pressure after AMI**

AMI may results in decreased left ventricular (LV) pumping function and thereby increasing LV filling pressures. The increased LV filling pressures transmits backwards into the lung circulation, leading to an increase in the pulmonary artery pressure (PAP). The elevated PAP is frequently associated with a reactive increase in pulmonary vascular resistance (PVR), resulting in a further increase in PAP\(^{22}\). Thus, the pulmonary circulation after AMI is characterized by elevated PAP and PVR, which increases the afterload of the right ventricle (RV) and may contribute to RV dysfunction and eventually RV failure\(^{23}\).

The mechanism underlying the pulmonary vasoconstriction after AMI is not completely understood, but may involve alterations in angiotensin-II\(^{24–26}\) as well as endothelial dysfunction\(^{22}\).
The pulmonary vascular endothelium is the predominant site for the angiotensin-converting enzyme which hydrolyses angiotensin-I to angiotensin-II. The pulmonary circulation is very sensitive to the vascular constrictive and proliferative effects of Angiotensin-II\(^{24,25}\), hence, after AMI develops progressive PH and RVH with important pulmonary structural remodeling characterized by myofibroblasts proliferation and a vicious circle of cardiopulmonary dysfunction\(^{26}\).

One other reason for elevated PAP level could be ischemic mitral valve regurgitation, which is a common complication after AMI and often associated with poor prognosis\(^{27–29}\).

The above-mentioned evidence and mechanisms indicate that patients with elevated sPAP after AMI might benefit from tailored and intensive treatment with angiotensin enzyme inhibitors and angiotensin receptor blockers, in order to prevent the development of post AMI heart failure and thereby to improve survival.

**Conclusions**

Elevated sPAP was an independent risk factor for one- and five-year all-cause mortality after AMI in very elderly patients and sPAP seems to be a better prognostic predictor for all-cause mortality than LVEF. The risk of all-cause mortality after AMI increased with increasing sPAP.

**Strengths and limitations**

The data in the present study was collected from the medical records from any of the two largest cardiology centers in Gothenburg. All the echocardiography studies were performed of echocardiography specialist at the department of clinical physiology and all echocardiography reports were reviewed of the authors. However, in this observational study, medical records were studied retrospectively. In addition, despite our efforts in collecting as much information as possible, some patient data were not available. Besides, despite adjustment, we cannot rule out residual confounding from unmeasured variables. The sample size was relatively small and included patients with STEMI and patients with non-STEMI. There was a limited number of patients with adequate data on sPAP. Nevertheless, the study showed a significant association between elevated sPAP and mortality in patients of 80 years of age or older who had suffered a myocardial infarction.

Furthermore, sPAP estimation by echocardiography includes an approximation of the right atrial pressure using inferior vena cava width and its respiratory variation. The gold standard would be right heart catheterization for measurement of pulmonary artery pressure, a data which was not available in our present study.

**Clinical implication**

In clinical practices after AMI, sPAP can be used as a marker of poor prognosis and a target in secondary preventive management to reduce the mortality and morbidity rates. As secondary preventive management after AMI, treatment with renin–angiotensin–aldosterone system (RAAS) inhibitors might improve the prognosis in patients with elevated sPAP after AMI. However, this is pure speculation. Treatment with ACEI/ARB had no significant impact on survival in the present study, which might be due to the fact that patients in the study had relatively low doses ACEI/ARB.

**Data availability**

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Received: 13 April 2022; Accepted: 6 July 2022

Published online: 23 July 2022

**References**

1. Jernberg, T. *et al.* Cardiovascular risk in post-myocardial infarction patients: Nationwide real-world data demonstrate the importance of a long-term perspective. *Eur. Heart J.* 36(19), 1163–1170 (2015).

2. Steg, P. G. *et al.* Global registry of acute coronary events investigators. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: Observations from the Global Registry of Acute Coronary Events (GRACE). *Circulation* 109, 494–499 (2004).

3. Sulo, G. *et al.* Heart failure complicating acute myocardial infarction: burden and timing of occurrence: A nation-wide analysis including 86,771 patients from the cardiovascular disease in Norway (CVDNOR) Project. *J. Am. Heart Assoc.* https://doi.org/10.1161/JAHA.115.002667 (2016).

4. Bahit, M. C. *et al.* Heart failure complicating non-ST-segment elevation acute coronary syndrome: Timing, predictors, and clinical outcomes. *J. Am. Coll. Cardiol.* HF 1, 223–229 (2013).

5. Juillièr, Y. *et al.* FAST-MI Investigators. Heart failure in acute myocardial infarction: a comparison between patients with or without heart failure criteria from the FAST-MI registry. *Rev. Esp. Cardiol.* 65, 326–333 (2012).

6. Ng, V. G. *et al.* The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. *Eur. Heart J. Acute Cardiovasc. Care* 3, 67–77 (2014).

7. Sutton, N. R. *et al.* The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry–Get With the Guidelines (GWGT) Medicare-linked database. *Am. Heart J.* 178, 65–73 (2016).

8. Van der Bijl, P. *et al.* Left ventricular post-infarct remodeling: Implications for systolic function improvement and outcomes in the modern era. *JACC Heart Fail.* 8, 131–140 (2020).

9. Ritsinger, V., Nyström, T., Saleh, N., Lagerqvist, B. & Norhammar, A. Heart failure is a common complication after acute myocardial infarction in patients with diabetes: A nationwide study in the SWEDHEART registry. *Eur. J. Prev. Cardiol.* 4, 2047487319901063 (2020).

10. Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. *N. Engl. J. Med.* 309(6), 331–336 (1983).

11. White, H. D. *et al.* Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. *Circulation* 76, 44–51 (1987).
12. Halkin, A. et al. Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction. *Am. J. Cardiol.* **96**, 325–331 (2005).
13. Solomon, S. D. et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. *Circulation* **11**, 3411–3419 (2005).
14. Delgado, V. Prognostic implications of elevated pulmonary artery pressure after ST-segment elevation myocardial infarction. *Am. J. Cardiol.* **118**, 326–331 (2016).
15. Moller, J. E., Hillis, G. S., Oh, J. K. & Pelikka, P. A. Prognostic importance of secondary pulmonary hypertension after acute myocardial infarction. *Am. J. Cardiol.* **96**, 199–203 (2005).
16. Fan, X. T., Wang, S. J., Mujahid, H. & Ji, X. P. Effect of elevated pulmonary artery systolic pressure on short-term prognosis in patients with acute myocardial infarction. *Angiology* **71**, 567–572 (2020).
17. Mutlak, D. et al. Utility of pulmonary hypertension for the prediction of heart failure following acute myocardial infarction. *Am. J. Cardiol.* **109**, 1254–1259 (2012).
18. Oh, J. K. et al. The noninvasive assessment of left ventricular diastolic function with two-dimensional and Doppler echocardiography. *J. Am. Soc. Echocardiogr.* **10**, 246–270 (1997).
19. Yildirimturk, O. et al. Assessment of right atrial pressure using echocardiography and correlation with catheterization. *J. Clin. Ultrasound* **39**, 337–343 (2011).
20. Kircher, B. J., Himelman, R. B. & Schiller, N. B. Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. *Am. J. Cardiol.* **66**, 493–496 (1990).
21. Miller, W. L., Grill, D. E. & Borlaug, B. A. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: Pulmonary hypertension and heart failure. *JACC Heart Fail.* **1**(4), 290–299 (2013).
22. Moraes, D. L., Colucci, W. S. & Givertz, M. M. Secondary pulmonary hypertension in chronic heart failure: The role of the endothelium in pathophysiology and management. *Circulation* **102**, 1718–1723 (2000).
23. Guaraccino, F. et al. Right ventricular failure: Physiology and assessment. *Minerva Anestesiol.* **71**, 307–312 (2005).
24. Lipworth, B. J. & Dagg, K. D. Vasoconstrictor effects of angiotensin II on the pulmonary vascular bed. *Chest* **105**, 1360–1364 (1994).
25. Morrell, N. W. et al. Angiotensin II stimulates proliferation of human pulmonary artery smooth muscle cells via the AT1 receptor. *Chest* **114**, 905–915 (1998).
26. Jasmin, J.-F., Calderone, A., Leung, T.-K., Villeneuve, L. & Dupuis, J. Lung structural remodeling and pulmonary hypertension after myocardial infarction: Complete reversal with irbesartan. *Cardiovasc. Res.* **58**, 621–631 (2003).
27. Bursi, F. et al. Heart failure and death after myocardial infarction in the community: The emerging role of mitral regurgitation. *Circulation* **111**, 295–301 (2005).
28. Aeronson, D. et al. Ischemic mitral regurgitation, and risk of heart failure after myocardial infarction. *Arch. Intern. Med.* **166**, 2362–2368 (2006).
29. Li, S., Barywani, S. & Fu, M. Prognostic significance of mitral regurgitation in long-term all-cause mortality in patients aged ≥ 80 years with acute coronary syndrome. *Int. J. Cardiol.* **20**(176), 340–345 (2014).

**Acknowledgements**

This work was supported by grants from the Västra Götalandsregionen and Göteborg Läkarsällskap, GLS, Sweden.

**Author contributions**

The corresponding author S.B.B. has built the database, performed the statistical analyses, generated tables, and figures, interpreted results and was the major contributor in writing the manuscript. Also M.J., P.H., Z.M. and S.K. have contributed in the interpreting of the results and writing the manuscript. All authors have read and approved the final manuscript.

**Funding**

Open access funding provided by University of Gothenburg.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to S.B.B.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022, corrected publication 2023